St. Jude Care & Treatment

Menu

Close

Recruiting

RESIST: Obesity Treatment for Leukemia Survivors

About this study 

People who survive childhood acute lymphoblastic leukemia can have health problems later in life. Many gain extra weight and may develop high blood pressure, high cholesterol, early signs of diabetes, or sleep problems. These issues can lower quality of life and raise long-term health risks, like risk for heart disease. Diet and exercise alone often do not lead to enough weight loss to improve these health problems. New medicines can help treat obesity and improve cardiometabolic health, but they may also cause muscle loss, which is already a concern for these survivors. 

This study tests a new approach that combines an FDA-approved anti-obesity medicine called tirzepatide with guided exercise and diet counseling. Participants will give themselves an injection of tirzepatide once a week. They will also take part in supervised online strength exercises (weight and resistance training) 3 times each week that is tailored to their ability. They will also receive support for healthy eating habits. The program lasts about 28 weeks. 

Researchers will track each person’s weight, body fat, and muscle over time. They will also check blood pressure, blood sugar, cholesterol, liver health, strength, and physical activity. Participants will also provide blood samples and get a DXA scan (low dose x-ray) to measure their body composition (fat and muscle) and an ultrasound of their liver. The study team will watch for side effects and see how well participants follow the medicine and exercise plans. 

This study will help researchers learn if combining tirzepatide with exercise and diet counseling is a safe and helpful way to improve weight and health. We want to learn if this approach is easy to follow and leads to weight loss in a way that will improve long-term health. 

Eligibility overview 

  • Adult survivor of childhood acute lymphoblastic leukemia treated with chemotherapy only  
  • Age 18 years or older  
  • Previously treated at St. Jude—now in SJLIFE or in continued follow-up in the After Completion of Therapy (ACT) Clinic 
  • Has obesity (BMI 30 or higher) or is overweight (BMI 27 or higher) with at least weight-related health condition (for example high blood pressure or high cholesterol) 
  • At least 2 years since completion of leukemia treatment  
  • Able to take weekly injections and take part in a remote resistance exercise program 

Request a referral

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

RESIST: Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL with Obesity

Study goal:

To test tirzepatide with resistance exercise and diet support to improve weight and cardiometabolic health in adult childhood ALL survivors.

Diagnosis:

Acute lymphoblastic leukemia (ALL)

Age:

18 years and older

Clinical trial categories:

Acute Lymphoblastic Leukemia (ALL)

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more